Vertaling van "ons oncology clinical " (Nederlands → Frans) :

7 ONS oncology nurse practitioners competencies 2007 ; ONS oncology clinical nurse specialist competencies 2008 8 Can Oncol Nurs J. 2011 Spring; 21(2):114-21, 106-13.Gaining a better understanding of the support function of oncology nurse
7 ONS oncology nurse practitioners competencies 2007 ; ONS oncology clinical nurse specialist competencies 2008 8 Can Oncol Nurs J. 2011 Spring; 21(2):114-21, 106-13.Gaining a better understanding of the support function of oncology

In the context of the National Cancer Plan and the FAMHP spearhead policy a scientific subgroup for oncology should be established within the CTTF in order to discuss critical aspects of clinical oncology research in adults and children at an advanced scientific level.
In the context of the National Cancer Plan and the FAMHP spearhead policy a scientific subgroup for oncology should be established within the CTTF in order to discuss critical aspects of clinical oncology research in adults and children at an advanced scientific level.

Bron: Journal of Clinical Oncology published online on June 17, 2013; DOI: 10.1200/JCO.2012.47.2738 Aimee R. Kreimer, Mattias Johansson, Tim Waterboer, et al.
Source : Journal of Clinical Oncology published online on June 17, 2013; DOI: 10.1200/JCO.2012.47.2738 Aimee R. Kreimer, Mattias Johansson, Tim Waterboer, et al.

Boek Clinical Nutrition for Oncology Patients
Livre Clinical Nutrition for Oncology Patients

Encouraging clinical trials and the inherent evaluation of applications for these trials, as well as the creation of a scientific subgroup for oncology, means that the FAMHP will need to have the necessary autonomy to attract the essential expertise for this relatively complex domain from the point of concept of innovative medicines.
Encouraging clinical trials and the inherent evaluation of applications for these trials, as well as the creation of a scientific subgroup for oncology, means that the FAMHP will need to have the necessary autonomy to attract the essential expertise for this relatively complex domain from the point of concept of innovative medicines.

[N.v.d.r.: volgens de American Society of Clinical Oncology blijft tamoxifen momenteel de eerste keuze als adjuvante hormonale behandeling van niet-gemetastaseerde borstkanker.]
[N.d.l.r.: d’après l’American Society of Clinical Oncology, le tamoxifène reste actuellement le traitement hormonal adjuvant de premier choix dans le cancer du sein non métastasé.]

Phase III data demonstrating a significant delay in tumor progression in patients with metastatic neuroendocrine tumors of the midgut who were treated with Sandostatin LAR were published recently in the “Journal of Clinical Oncology”.
Le «Journal d’Oncologie Clinique» a publié récemment les résultats de l’étude de phase III confirmant que Sandostatine LAR, administré à des patients atteints de tumeurs neuro-endrocrines métastasiques de l’intestin moyen, ralentissait considérablement la progression de la tumeur.

Oncology Gleevec/Glivec (USD 2.9 billion, +12% lc), a targeted therapy for some forms of chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST), has achieved sustained double-digit growth based on its leadership position in treating these cancers backed by new clinical data and regulatory approvals.
Oncologie Glivec/Gleevec (USD 2,9 milliards, +12% en m. l.), traitement ciblé contre certaines formes de leucémie myéloïde chronique (LMC) et de tumeurs stromales gastrointestinales (GIST), a enregistré une croissance soutenue à deux chiffres, grâce à sa position de leader dans le traitement de ces cancers, étayée par de nouveaux résultats cliniques et par des autorisations de mise sur le marché.

Interview met Mace Rothenberg, Senior Vice President Clinical Development and Medical Affairs – Pfizer Oncology
Interview avec Mace Rothenberg, Senior Vice President Clinical Development and Medical Affairs – Pfizer Oncology

Op basis van deze bemoedigende resultaten was het besluit van de American Society of Clinical Oncology dat na de menopauze, de optimale adjuverende hormonale behandeling een aromatase-inhibitor zou moeten bevatten [zie Folia januari 2006 en augustus 2006 ].
Sur base de ces résultats encourageants, l’ American Society of Clinical Oncology a conclu que, après la ménopause, le traitement hormonal adjuvant optimal devrait inclure un inhibiteur de l’aromatase [voir Folia de janvier 2006 et août 2006 ].